miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms

Carcinogenesis

Volumn 33, Issue 5, 2012, Pages 1014-1021

  Senanayake, Upeka ^a   Das, Suman ^a   Vesely, Paul ^a   Alzoughbi, Wael ^a   Fröhlich, Leopold F ^a   Chowdhury, Pooja ^a   Leuschner, Ivo ^b   Hoefler, Gerald ^a   Guertl, Barbara ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR 2; MESSENGER RNA; MICRORNA; MICRORNA 141; MICRORNA 192; MICRORNA 194; MICRORNA 200C; MICRORNA 215; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BLASTEMA; CHILDHOOD CANCER; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KIDNEY PARENCHYMA; NEPHROBLASTOMA; PATHOGENESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84860488299     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs126     Document Type: Article

References (61)

1. Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-297.
2. Chua, J.H. et al. (2009) MicroRNAs: biogenesis, functions and applications. Curr. Opin. Mol. Ther., 11, 189-199.
3. Bhatt, K. et al. (2011) MicroRNAs in kidneys: biogenesis, regulation, and pathophysiological roles. Am. J. Physiol. Renal Physiol., 300, F602-F610.
4. Wessely, O. et al. (2010) MicroRNAs in kidney development: lessons from the frog. RNA Biol., 7, 296-299.
5. Harvey, S.J. et al. (2008) Podocyte-specific deletion dicer alters cytoskeletal dynamics and causes glomerular disease. J. Am. Soc. Nephrol., 19, 2150-2158.
6. Ho, J. et al. (2008) Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J. Am. Soc. Nephrol., 19, 2069-2075.
7. Foulkes, W.D. et al. (2011) Extending the phenotypes associated with DICER1 mutations. Hum. Mutat., 32, 1381-1384.
8. Slade, I. et al. (2011) DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J. Med. Genet., 48, 273-278.
9. Murphy, W.M. et al. (2004) Kidney tumors in children. In Murphy, W.M. (eds) et al. Tumors of the Kidney, Bladder, and Related Urinary Structures. Armed Forces Institute of Pathology, Washington, DC, pp 1-100.
10. Dekel, B. et al. (2002) Engraftment and differentiation of human metanphroi into functional mature nephrons after transplantation into mice is accompanied by a profile of gene expression similar to normal human kidney development. J. Am. Soc. Nephrol., 13, 977-990.
11. Beckwith, B.J. (1993) Prescursor lesions of Wilms tumor: clinical and biological implications. Med. Pediatr. Oncol., 21, 158-168.
12. Coppes, M.J. et al. (1999) Factors affecting the risk of contralateral Wilms tumor development: a report from the NationalWilms Tumor Study Group. Cancer, 85, 1616-1625.
13. Bergeron, C. et al. (2001) Does nephroblastomatosis influence the natural history and relapse rate in Wilms' tumour? A single center experience over 11 years. Eur. J. Cancer, 37, 385-391.
14. Drake, K.M. et al. (2009) Loss of heterozygosity at 2q37 in sporadicWilms tumor: putative role of miR-562. Clin. Cancer Res., 15, 5985-5992.
15. Veronese, A. et al. (2010) Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res., 70, 3140-3149.
16. Imam, J.S. et al. (2010) Micro-RNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene, 29, 4971-4979.
17. Sun, Y. et al. (2004) Development of a micro-array to detect human and mouse micro RNAs and characterization of expression in human organs. Nucleic Acids Res., 32, e188.
18. Saal, S. et al. (2009) MicroRNAs and the kidney: coming of age. Curr. Opin. Nephrol. Hypertens., 18, 317-323.
19. Shi, Y. et al. (2003) Mechanisms of TGF-b signalling from cell membrane to the nucleus. Cell, 113, 685-700.
20. Shah, M.M. et al. (2004) Branching morphogenesis and kidney disease. Development, 131, 1449-1462.
21. Ying, S.Y. et al. (1997) Activins and activin receptors in cell growth. Proc. Soc. Exp. Biol. Med., 214, 114-122.
22. Levy, L. et al. (2006) Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev., 17, 41-58.
23. Maeshima, A. et al. (2003) Activin A produced by ureteric bud is a differentiation factor for metanephric mesenchyme. J. Am. Soc. Nephrol., 14, 1523-1534.
24. Maeshima, A. et al. (2001) Involvement of the activin-follistatin system in tubular regeneration after renal ischemia in rats. J. Am. Soc. Nephrol., 12, 1685-1695.
25. Papadopoulos, G.L. et al. (2009) DIANA-mirPath: integrating human and mouse microRNAs in pathways. Bioinformatics, 25, 1991-1993.
26. Maragkakis, M. et al. (2009) DIANA-microTweb server: elucidatingmicroRNA functions through target prediction. Nucleic Acids Res., 37, W273-W276.
27. Balaguer, F. et al. (2010) Epigenetic Silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res., 70, 6609-6618.
28. Kanehisa, M. et al. (2000) KEGG-Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res., 28, 27-30.
29. Cheng, A.M. et al. (2005) Antisense inhibition of human mitRNAs and indication for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res., 33, 1290-1297.
30. Babashah, S. et al. (2011) The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur. J. Cancer, 47, 1127-1137.
31. Lu, J. et al. (2005) MicroRNA expression profiles classify human cancers. Nature, 435, 834-838.
32. Esquela-Kerscher, A. et al. (2006) Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer, 6, 259-269.
33. White, N.M. et al. (2010) MicroRNAs: exploring a new dimension in the pathogenesis of kidney cancer. BMC Med., 8, 65.
34. Ribal, M.J. (2011) Molecular profiling of renal cancer: the journey to clinical application. Eur. Urol., 59, 731-733.
35. Cho, W.C. (2010a) MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem. Cell Biol., 42, 1273-1281.
36. Cho, W.C. (2010b) MicroRNAs in cancer-from research to therapy. Biochim. Biophys. Acta, 1805, 209-217.
37. Davidson, L.A. et al. (2009) n-3 polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis, 30, 2077-2084.
38. Braun, C.J. et al. (2008) p-53 responsive MicroRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res., 68, 10094-10104.
39. Wijnhoven, B.P. et al. (2010) MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br. J. Surg., 97, 853-861.
40. Verschuur, A.C. et al. (2010) Stromal and epithelial predominant Wilms tumours have an excellent outcome: the SIOP 93 01 experience. Pediatr. Blood Cancer, 55, 233-238.
41. Sredni, S.T. et al. Renal Tumor Committee of the Children's Oncology Group (2009) Subsets of very low risk Wilms tumor show distinctive gene expression, histologic and clinical features. Clin. Cancer Res., 15, 6800-6809.
42. Du, Y. et al. (2009) Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J. Gastroenterol., 44, 556-561.
43. Jung, M. et al. (2009) MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J. Cell. Mol. Med., 13, 3918-3928.
44. Catto, J.W. et al. (2011) MicroRNA in prostate, bladder and kidney cancer: a systematic review. Eur. Urol., 59, 671-681.
45. Youssef, Y.M. et al. (2011) Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur. Urol., 59, 721-730.
46. Redova, M. et al. (2011) MicroRNAs and their target gene networks in renal cell carcinoma. Biochem. Biophys. Res. Commun., 405, 153-156.
47. Fridman, E. et al. (2010) Accurate molecular classification of renal tumors using microRNA expression. J. Mol. Diagn., 12, 687-696.
48. Liou, L.S. et al. (2010) Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma. BMC Syst. Biol., 4, 51.
49. Ioro, M.V. et al. (2007) MicroRNA signatures in human ovarian cancer. Cancer Res., 67, 8699-8702.
50. Pode-Shakked, N. et al. (2009) Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population. J. Cell. Mol. Med., 13, 1792-1808.
51. Derynck, R. et al. (2001) TGF-β signaling in tumor suppression and cancer progression. Nat. Genet., 29, 117-129.
52. Grady, W.M. et al. (1999) Mutation inactivation of transforming growth factor b receptor type II in microsatellite stable colon cancers. Cancer Res., 59, 320-324.
53. Hahn, S.A. et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome18q21.1. Science, 271, 350-353.
54. Babel, I. et al. (2009) Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol. Cell. Proteomics, 8, 2382-2395.
55. DiSimone, N. et al. (2002) Regulation of endometrial adenocarcinoma cell proliferation by activin-A and its modulation by 17beta-estradiol. Mol. Cell. Endocrinol., 192, 187-195.
56. Takahashi, M. et al. (2008) Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation. J. Endocrinol., 199, 445-455.
57. Choi, K.C. et al. (2001) Differential expression of activin/inhibin subunit and activin receptor mRNAs in normal and neoplastic ovarian surface epithelium (OSE). Mol. Cell. Endocrinol., 174, 99-110.
58. Mabuchi, Y. et al. (2006) Immunohistochemical localization of inhibin and activin subunits, activin receptors, and Smads in ovarian clear cell adenocarcinoma. Oncol. Rep., 15, 291-296.
59. Vuononvirta, R. et al. (2009) Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development. Clin. Cancer Res., 15, 2723-2730.
60. Zhang, C. et al. (2011) Is atypical adenomatous hyperplasia of the prostate a precursor lesion? Prostate, 71, 1746-1751.
61. Bodmer, W.F. (2006) Cancer genetics: colorectal cancer as a model. J. Hum. Genet., 51, 391-396.